DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ocular motility disease — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOcular motility disease maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedPonatinibApproved drug
Structures already discussed alongside ocular motility disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance — Ponatinib has a real, experimentally solved structure in complex with this target (PDB 3IK3, 1.9 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 0lidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3IK3 · 1.9 Å · ligand Ponatinib (0LI). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 case report describes a 50-year-old man with chronic myeloid leukaemia who developed a sight-threatening granulomatous panuveitis in both eyes, with choroidal effusions and neurosensory retinal detachments, after three months of treatment with the tyrosine kinase inhibitor ponatinib. All uveitis investigations were normal except for a positive interferon-gamma release assay suggesting previous tuberculosis exposure. Discontinuation of ponatinib led to resolution of the signs and improvement in visual acuity. The authors note that ponatinib use may be associated with a uveitic phenotype reminiscent of Harada’s disease.
A 2024 case report describes a 15-year-old Indian male with myelin oligodendrocyte glycoprotein-associated disease (MOGAD) who had severe loss of vision in one eye followed by a recurrent attack of optic neuritis in the fellow eye. Other ophthalmic findings included macular neuroretinopathy, retinal haemorrhages, severe optic nerve head oedema, perineuritis, and orbital enhancement on MRI. The patient responded dramatically to intravenous pulse steroids, and relapses were controlled with long-term immunomodulation therapy. The authors emphasise the need for early treatment with pulse steroids in MOGAD.
A 2009 review of a textbook on ocular disease pathology notes that the work is organised by mechanisms rather than anatomic areas, and covers genetic and cell biology of ocular disease. A 1964 book on medical management of ocular disease is described as a compilation by 18 authors covering diagnosis and medical management, though some chapters are sketchy and little more than lists.
No controlled trials exist for any drug specifically for ocular motility disease in these abstracts. The evidence is limited to two single case reports of adverse effects or disease manifestations, not treatment of ocular motility disorders. What is missing is any prospective trial, any patient stratification by motility phenotype, and any funding for a dedicated study of drug effects on ocular motility.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ocular Immunology and Inflammation · 2021 · 5 citations
Ponatinib Inducing a Panuveitis with Choroidal Effusions and Neurosensory Retinal Detachment in a Patient with Chronic Myeloid Leukaemia
AbstractCASE SUMMARY: We present the case of a 50 year old male patient being treated for chronic myeloid leukemia by the tyrosine kinase inhibitor, Ponatinib. After 3 months of treatment, he developed a sight-threatening granulomatous panuveitis in both eyes, with choroidal effusions and neurosensory retinal detachments. Except for a positive interferon-gamma release assay suggesting previous Tuberculosis exposure, all uveitis investigations were normal. Discontinuation of the suspected causative drug led to resolution of signs and a consequent improvement in visual acuity. CONCLUSION: Ponatinib use may be associated with with a uveitic phenotype that is reminiscent of Harada's disease. We compare and contrast this rare ocular phenomenon with Vogt-Koyanagi-Harada syndrome and discuss a possible immunological basis.
Ocular Immunology and Inflammation · 2024 · 0 citations
Clinical Spectrum of Ophthalmic Manifestations in Myelin Oligodendrocyte Glycoprotein-Associated Disease (MOGAD): A Comprehensive Case Report
AbstractPURPOSE: To describe diverse ocular manifestations in a patient with Myelin oligodendrocyte glycoprotein-associated disease (MOGAD). METHODS: A 15-year-old Indian male had severe loss of vision in one eye, followed by a recurrent attack of optic neuritis in the fellow eye a few weeks later. He had a history of vision loss, speech disturbances, altered sensorium and was a confirmed case of Myelin oligodendrocyte glycoprotein-associated disease (MOGAD). Apart from optic neuritis, other rare ophthalmic associations, namely, macular neuroretinopathy, retinal haemorrhages, severe optic nerve head edema, peri neuritis, and orbital enhancement on magnetic resonance imaging (MRI) were noted. RESULTS: He responded dramatically to treatment with intravenous pulse steroids and relapses were controlled with long-term immunomodulation therapy. CONCLUSION: This case report reiterates the need for early treatment with pulse steroids in MOGAD and depicts the heterogeneous involvement of various ocular structures in the disease.
Journal of Neuro-Ophthalmology · 2009 · 0 citations
Garner and Klintworth's Pathobiology of Ocular Diseases, 3rd Edition
AbstractGordon K. Klintworth, PhD, and Alec Garner, MD, PhD. Informa Healthcare, New York, 2008. ISBN 978-0-8493-9816-2, $699.95. Scope: This two-volume set encompasses current knowledge of anatomic pathology, cell biology, molecular biology, and biochemistry of ocular disease. Numerous authors provide a multidisciplinary depth of information unmatched in current eye pathology texts. The book is organized by mechanisms rather than anatomic areas. Unification of the chapter format is achieved from a set outline permitting easy transition between chapters despite the multiple writers. A great deal of space has been allocated for detailed presentations of etiologic aspects of various disease processes. The intended audience includes ocular pathologists, neuropathologists, ophthalmologists, and scientists working in disciplines such as immunology, genetics, and cell biology. Strengths: This unique textbook is designed to promote the understanding of disease processes. It is meticulously referenced and contains an enormous amount of detail concerning the genetics and cell biology of ocular disease. Most chapters provide interesting historical information, superb pathophysiologic explanations, and exhaustive tables. The outstanding quality of many chapters such as Genetic Disorders of the Cornea, authored by Klintworth, exemplifies the expertise of the authors. Weaknesses: Illustrations, all black and white, vary in quality. The ambitious attempt to explore the pathogenesis of so many topics has taken some authors to their limits and accounts for some omissions. For example, tear lipocalin, a siderophore binding protein, is overlooked in the discussion of microbial competition for iron in the tear film. To stay current, the work will require frequent updates. Recommended Audience: This is an excellent reference textbook for scientists and pathologists who work with the eye. The book's comprehensive nature may be overwhelming as a primer for residents training in ophthalmology, but the book will be a superb reference source for them. Critical Appraisal: This book is an outstanding contribution to the field of ophthalmic pathology. It provides a comprehensive overview not found in any other work in our discipline. Ben Glasgow, MD Department of Pathology and Laboratory Medicine University of California, Los Angeles Los Angeles, California
AbstractEdited by one of the pioneers in ocular corticosteroid therapy, this is a herculean effort by 18 authors to cover all aspects of diagnosis and medical management of ocular disease as well as the indications for surgery. In this compendium some chapters are extremely sketchy and little more than lists. Most, however, represent thorough and authoritative interpretations of important, difficultto-manage conditions. As might be expected, some conditions are slighted and others are considered several times. In general, however, an attempt is made to correlate material between chapters and to present a generally unified coverage with little conflict and only occasional overlap. Background references for many opinions are not considered in detail because of the extensive scope of the material covered in the book, but most chapters are good expositions by authors of maturity and experience who indicate the methods they prefer for the management of ocular disease. The book is
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
